BRPI0410915A - composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit - Google Patents

composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit

Info

Publication number
BRPI0410915A
BRPI0410915A BRPI0410915-5A BRPI0410915A BRPI0410915A BR PI0410915 A BRPI0410915 A BR PI0410915A BR PI0410915 A BRPI0410915 A BR PI0410915A BR PI0410915 A BRPI0410915 A BR PI0410915A
Authority
BR
Brazil
Prior art keywords
interferon
protein
gene
pharmaceutical composition
delivery
Prior art date
Application number
BRPI0410915-5A
Other languages
English (en)
Inventor
Heidrun Engler
Tattanahalli L Nagabhushan
Stephen Youngster
Robert Connor
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/455,215 external-priority patent/US20040014709A1/en
Application filed by Canji Inc filed Critical Canji Inc
Publication of BRPI0410915A publication Critical patent/BRPI0410915A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, MéTODO PARA FORNECER UM INTERFERON A UM SUJEITO MAMìFERO, E, KIT". Proporciona-se métodos e composições farmacêuticas para administrar terapia de genes ou proteína em órgãos ou tecidos apresentando uma camada de células epiteliais. Uma proteína ou acido nucleico que codifica a proteína é administrada em um órgão ou tecido-alvo em combinação com tratamento com um agente intensificador de fornecimento que aumenta o fornecimento do interferon ou ácido nucleico às células dos órgãos ou tecidos-alvos. Os métodos e combinações são particularmente úteis no tratamento de cânceres e outras condições responsivas à terapia com interferon. Um método exemplar compreende a administração intravesicular transuretral na bexiga de uma quantidade terapeuticamente eficazes de uma composição farmacêutica que compreende um interferon-alfa ou um gene de fornecimento de genes que codifica o interferon e SYN3 ou um homólogo ou análogo de SYN3. Na bexiga urinária, é possível observar um aumento de 10 até 1000 vezes na atividade e nos níveis de interferon com o uso de uma formulação de SYN3, em oposição a uma formulação de PBS do mesmo sistema de fornecimento de proteína de interferon ou gene de interferon.
BRPI0410915-5A 2003-06-04 2004-06-04 composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit BRPI0410915A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47592603P 2003-06-04 2003-06-04
US10/455,215 US20040014709A1 (en) 1996-01-08 2003-06-04 Methods and compositions for interferon therapy
PCT/US2004/017788 WO2004108088A2 (en) 2003-06-04 2004-06-04 Methods and compositions for interferon therapy

Publications (1)

Publication Number Publication Date
BRPI0410915A true BRPI0410915A (pt) 2006-06-27

Family

ID=33513856

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410915-5A BRPI0410915A (pt) 2003-06-04 2004-06-04 composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit

Country Status (9)

Country Link
US (1) US20050025742A1 (pt)
EP (2) EP1628624A2 (pt)
JP (3) JP2006526661A (pt)
KR (1) KR20060012661A (pt)
AU (2) AU2004245074A1 (pt)
BR (1) BRPI0410915A (pt)
CA (2) CA2527658A1 (pt)
NO (1) NO20060019L (pt)
WO (1) WO2004108088A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
AU2002366809A1 (en) * 2001-12-20 2003-07-09 Schering-Plough Corporation Syn3 compositions and methods
US20030198624A1 (en) * 2002-03-02 2003-10-23 Mohapatra Shyam S. Method of treating allergic disease and asthma by recombinant adenovirus- and adeno-associated virus- mediated IFN-gamma gene transfer
CA2484251C (en) * 2002-04-30 2015-06-23 University Of South Florida Materials and methods for inhibition of respiratory syncytial virus infection
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
CA2516188C (en) * 2003-02-14 2012-04-17 University Of South Florida Chitosan-derivatives for gene delivery and expression
CN100429220C (zh) * 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
WO2005058368A1 (en) * 2003-12-10 2005-06-30 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
US20050266093A1 (en) * 2004-04-27 2005-12-01 Mohapatra Shyam S Nanogene therapy for cell proliferation disorders
TWI305230B (en) * 2004-06-25 2009-01-11 Univ Feng Chia Nucleic acid construct and expression vector for enhancing the production of recombinant protein, and method for the massive production of recombinant protein
JP4621743B2 (ja) 2004-12-13 2011-01-26 カンジ，インコーポレイテッド 複製欠損アデノウイルスの産生のための細胞株
JP5097714B2 (ja) 2005-12-12 2012-12-12 カンジ，インコーポレイテッド Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
CA3021073A1 (en) 2016-04-14 2017-10-19 Trizell Ltd. Viral vector stabilization

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5298222A (en) * 1989-08-09 1994-03-29 Osteotech, Inc. Process for disinfecting musculoskeletal tissue and tissues prepared thereby
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5118512A (en) * 1990-01-23 1992-06-02 Osteotech, Inc. (A Delaware Corp.) Process for cryopreserving biological materials and materials prepared thereby
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5831062A (en) * 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy

Also Published As

Publication number Publication date
JP2007269808A (ja) 2007-10-18
KR20060012661A (ko) 2006-02-08
CA2528136A1 (en) 2004-12-16
AU2004245074A1 (en) 2004-12-16
WO2004108088A3 (en) 2006-04-20
AU2004245995A1 (en) 2004-12-16
US20050025742A1 (en) 2005-02-03
NO20060019L (no) 2006-03-03
EP1628624A2 (en) 2006-03-01
CA2527658A1 (en) 2004-12-16
JP2006526661A (ja) 2006-11-24
JP2007526219A (ja) 2007-09-13
EP1629085A2 (en) 2006-03-01
WO2004108088A2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
BRPI0410915A (pt) composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit
US10478394B2 (en) Compositions and methods to promote wound healing
CN101500589B (zh) 半乳糖凝集素组合物及其治疗干眼综合症的应用
US8980840B2 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
Alexander et al. Liposome-mediated gene transfer and expression via the skin
Corona et al. Pharmacological mitigation of fibrosis in a porcine model of volumetric muscle loss injury
CZ475599A3 (cs) Použití nukleové kyseliny k výrobě léčiva pro genovou terapii, které se injikuje do příčně pruhovaného svalstva
US20190328770A1 (en) Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
JP2004530401A (ja) 細胞への核酸の送達を促進する方法および成分
JP2015057431A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
CN111050785A (zh) 局部皮肤营养不良状况的治疗
KR20170058384A (ko) 조기 난포 활성화의 방지 방법
Nghiem et al. Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells
Hirsch et al. Insulin‐like growth factor‐1 gene therapy and cell transplantation in diabetic wounds
CN110636854A (zh) 非黑素瘤皮肤癌(nmsc)的预防和治疗
Tredget et al. Regulation of collagen synthesis and messenger RNA levels in normal and hypertrophic scar fibroblasts in vitro by interferon alfa‐2b
JP2002513775A (ja) 細胞の中へのポリヌクレオチドのトランスフェクションを改良する治療組成物を調製するためのヌクレアーゼインヒビターまたはインターロイキン−１０（ｉｌ−１０）の使用、および遺伝子治療に有用な組成物
TW201016229A (en) Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease
Lossos et al. The effect of suramin on bleomycin-induced lung injury
JP2006505290A5 (pt)
CN100368540C (zh) 重组细胞球蛋白（Cytoglobin)的生产方法及其用途
CN105311636B (zh) 一种抗疱疹病毒软膏剂及其制备方法
Ghahary et al. Expression of fibronectin messenger RNA in hypertrophic and normal dermal tissues and in vitro regulation by interferon alfa‐2b
KR101607629B1 (ko) miRNA를 이용한 C형 간염 바이러스 감염 질환의 예방 또는 치료
US8609147B2 (en) Use of deuterium oxide for treatment of herpes virus-based diseases of the skin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.